Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness. OBJEC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Intern Med
Main Authors: Gupta, Shruti, Wang, Wei, Hayek, Salim S., Chan, Lili, Mathews, Kusum S., Melamed, Michal L., Brenner, Samantha K., Leonberg-Yoo, Amanda, Schenck, Edward J., Radbel, Jared, Reiser, Jochen, Bansal, Anip, Srivastava, Anand, Zhou, Yan, Finkel, Diana, Green, Adam, Mallappallil, Mary, Faugno, Anthony J., Zhang, Jingjing, Velez, Juan Carlos Q., Shaefi, Shahzad, Parikh, Chirag R., Charytan, David M., Athavale, Ambarish M., Friedman, Allon N., Redfern, Roberta E., Short, Samuel A. P., Correa, Simon, Pokharel, Kapil K., Admon, Andrew J., Donnelly, John P., Gershengorn, Hayley B., Douin, David J., Semler, Matthew W., Hernán, Miguel A., Leaf, David E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577201/
https://ncbi.nlm.nih.gov/pubmed/33080002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.6252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados